You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • FRI0204 Long-term benefits of 4-weekly certolizumab pegol monotherapy and combination therapy on household productivity and social participation in rheumatoid arthritis: 5-year results from an open-label extension study

Article metrics

Article menu
Download PDFPDF
Poster Presentation
Rheumatoid arthritis - anti-TNF therapy
FRI0204 Long-term benefits of 4-weekly certolizumab pegol monotherapy and combination therapy on household productivity and social participation in rheumatoid arthritis: 5-year results from an open-label extension study

 

Online download statistics by month:

Online download statistics by month: February 2014 to March 2024

AbstractFullPdf
Feb 2014902
Mar 2014401
Apr 2014700
May 2014300
Jun 2014200
Jul 2014200
Sep 2014100
Oct 2014602
Nov 2014701
Dec 2014400
Jan 2015300
Feb 2015300
Mar 2015701
Apr 2015500
May 2015200
Jul 2015300
Aug 2015400
Sep 2015300
Oct 2015600
Nov 2015702
Jan 2016100
Feb 2016400
Mar 2016401
May 2016400
Jun 2016800
Jul 2016500
Aug 2016400
Sep 2016400
Oct 2016300
Nov 2016300
Dec 2016300
Jan 2017500
Feb 2017100
Mar 2017500
Apr 2017500
May 2017400
Jun 2017300
Aug 2017400
Sep 2017600
Oct 2017800
Nov 2017600
Dec 2017800
Jan 2018800
Mar 20182401
Apr 20181000
May 20182801
Jun 20181000
Jul 20181000
Aug 20181200
Sep 2018600
Oct 2018800
Nov 20182000
Dec 2018600
Jan 2019800
Feb 20191000
Apr 2019200
May 2019200
Jul 2019200
Nov 20191000
Feb 2020200
Apr 2020200
Jul 2020200
Sep 2020600
Oct 2020200
Nov 2020200
Dec 2020500
Jan 2021200
Mar 2021300
Apr 2021200
Nov 20211000
Dec 20211100
Feb 2022200
Mar 2022200
Apr 2022500
May 2022200
Jun 2022200
Jul 20221600
Aug 2022601
Sep 2022200
Nov 20221000
Dec 2022400
Jan 20231000
Feb 2023500
Mar 2023200
Apr 2023500
May 20231000
Jul 2023200
Aug 2023801
Sep 2023800
Oct 2023200
Dec 2023800
Jan 2024200
Mar 2024400
Total528014